Research programme: CD8 antagonists - MediGene

Drug Profile

Research programme: CD8 antagonists - MediGene

Alternative Names: YourDex

Latest Information Update: 30 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avidex
  • Developer MediGene Ltd
  • Class Proteins
  • Mechanism of Action CD8 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis; Transplant rejection

Most Recent Events

  • 12 Dec 2007 Preclinical trials in Psoriasis in United Kingdom (Parenteral)
  • 12 Dec 2007 Preclinical trials in Transplant rejection in United Kingdom (Parenteral)
  • 29 Sep 2006 Avidex is acquired by MediGene AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top